Anticataleptic properties of α2 adrenergic antagonists in the crossed leg position and bar tests: Differential mediation by 5-HT 1A receptor activation

Psychopharmacology

Volumn 177, Issue 4, 2005, Pages 373-380

  Kleven, Mark S ^a   Assié, Marie Bernadette ^a   Cosi, Cristina ^a   Barret Grévoz, Catherine ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

2 Adrenergic receptor; 5 HT1A receptor; Antipsychotic; Catalepsy; Dopamine D2 receptor; Extrapyramidal side effect; Neuroleptic; Schizophrenia

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ATIPAMEZOLE; EFAROXAN; HALOPERIDOL; IDAZOXAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; YOHIMBINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICATALEPTIC ACTIVITY; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MEGADOSE; EXPERIMENTAL TEST; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANIMAL BEHAVIOR; BODY POSTURE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; RADIOASSAY; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CATALEPSY; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HALOPERIDOL; MALE; PIPERAZINES; POSTURE; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, ADRENERGIC, ALPHA-2; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 13644266947     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1970-z     Document Type: Article

References (42)

1. Al Shabibi UM, Doggett NS (1978) On the central noradrenergic mechanism involved in haloperidol-induced catalepsy in the rat. J Pharm Pharmacol 30:529-531
2. Assié MB, Sleight AJ, Koek W (1993) Biphasic displacement of (3H)YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol 237:183-189
3. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37-46
4. Broekkamp CL, Oosterloo SK, Berendsen HH, van Delft AM (1988) Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch Pharmacol 338:191-195
5. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1-26
6. Haapalinna A, Leino T, Heinonen E (2003) The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedeberg's Arch Pharmacol 368:342-351
7. 2 adrenoceptor blockade. Science 286:105-107
8. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70
9. Hubert JJ (1984) Bioassay. Kendall/Hunt, Dubuque
10. 2- adrenoreceptors in the rat brain. Mol Neuropharmacol 1:219-229
11. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518
12. 2- adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms. Neuropsychopharmacology 28:872-879
13. 1A receptor. Eur J Pharmacol 441:137-140
14. 2C-adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33-40
15. 2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550-1556
16. 1A receptors. Arzneimittelforschung Drug Res 44:1-3
17. 2A/2C antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Ther 282:747-759
18. 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol 13:264-267
19. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia-comparison with the atypical neuroleptic, clozapine. Br J Pharmacol 168:571-579
20. 1A autoreceptors modulating serotonin synthesis in the rat brain in vivo. Neurosci Lett 218:111-114
21. 2 adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 360:603-608
22. McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40:885-887
23. Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 295:853-861
24. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356-1373
25. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Coge F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35:79-95
26. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
27. Neal-Beliveau BS, Joyce JN, Lucki I (1993) Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217
28. 35S] GTPgammaS binding study. Eur J Pharmacol 355:245-256
29. 2A adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 358:197-206
30. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol 8:193-195
31. Nutt DJ, Lalies M, Hudson A (1993) The effects of alpha-2-adrenoceptor antagonists on extracellular dopamine concentrations in the rat striatum. In: Colpaert F, Briley M (eds) Noradrenergic mechanisms in Parkinson disease. Academic, New York, pp 159-172
32. 1A receptor agonist properties. Eur J Pharmacol 356:189-192
33. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144:20-29
34. 1A receptors. Eur J Pharmacol 395:143-147
35. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453:217-221
36. Sastre-Coll A, Esteban S, Garcia-Sevilla JA (1999) Effects of imidazoline receptor ligands on monoamine synthesis in the rat brain in vivo. Naunyn Schmiedeberg's Arch Pharmacol 360:50-62
37. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe IJA, Heym J (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113
38. Tallarida RJ, Murray RG (1987) Manual of pharmacological calculations with computer programs. Springer, Berlin Heidelberg New York
39. Wadenberg M-L, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Trans Gen Sect 83:43-53
40. Winer BJ (1971) Statistical principles in experimental design. McGraw Hill, New York
41. Winter JC, Rabin RA (1992) Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther 263:682-689
42. 2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol 462:83-89